Aether Industries Limited: CRAMS and CEM reach 65.97% of revenue
Key highlights
- CRAMS and CEM together contributed 65.97% of Aether Industries' quarterly revenue after selected LSM lines were reassigned to CEM.
- Aether's total sales increased 23.96% year on year and 6.33% quarter on quarter.
- Aether's 1H FY27 EBITDA margin rose 88 basis points year on year to 31.64%.
- Inventory days increased to 172 at September 30, 2026, from 151 at March 31, 2026, as the company prepared for CEM deliveries and Magnum production.
powered by IRIS

Aether Industries Limited said Contract Research and Manufacturing Services (CRAMS) and Contract Exclusive Manufacturing (CEM) together supplied 65.97% of quarterly revenue after selected Large Scale Manufacturing (LSM) lines were reassigned to CEM. Total sales increased 23.96% year on year and 6.33% quarter on quarter.
Know Aether Industries inside out
Results, valuation, peers and who's buying, in one view.
Why is Aether moving production from LSM to CEM?
Aether is moving selected production lines from LSM to CEM to support the ramp-up of contract manufacturing work. LSM contributed 33.35% of sales during the quarter, while CRAMS and CEM together contributed 65.97%, near management's previously stated 70% revenue-mix target for the two businesses.
The change affected LSM's near-term sales profile. LSM revenue grew 1.23% year on year but declined 8.35% quarter on quarter, which Aether attributed primarily to the deliberate reallocation of selected lines to CEM. LSM product prices increased 27.45% year on year and 3.39% quarter on quarter, partly offsetting the sequential volume moderation.
Aether said the reallocation also moderated pharmaceutical and agrochemical sales, which accounted for 26.58% and 7.86% of quarterly revenue, respectively. Management expects these sectors to recover as a pharmaceutical product at Magnum ramps during the third and fourth quarters of financial year 2027 (Q3 and Q4 FY27) and a new agrochemical product is commercialised in Q4 FY27.
How did Aether's CRAMS and CEM businesses perform?
Aether's CEM business grew approximately 50.03% year on year, while CRAMS expanded approximately 23.91% year on year. Both growth rates exceeded LSM's 1.23% year-on-year increase as total sales rose 23.96% year on year.
CRAMS added research and development projects across several sectors, with Oil and Gas and Material Science representing the largest portions of its project portfolio. The division was working on more than 65 projects during the quarter and moved its research and development operations from a 24-hour, six-day schedule to a 24-hour, seven-day schedule. Aether also commenced a silicon project with Dow Chemicals focused on complex chemical engineering design.
CEM's reported quarterly revenue included Rs 72 crore from the Baker Hughes contract at the Strata site and Rs 15 crore from commercial sales of new pilot-plant products. Strata underwent piping modifications during the quarter to support a wider product portfolio, and management expects additional Baker Hughes products from Q3 FY27.
Capacity utilisation increased at all three listed plants between Q1 FY27 and Q2 FY27. At Ascend, one half of the site is dedicated to Milliken Chemical and Textile (India) Company, while the other supports a leading European customer's CEM contract; Strata reached 61% utilisation as Baker Hughes volumes and products progressed.
Got a follow-up? Ask IRIS
Which projects could expand Aether's contract-led mix?
Aether identified Magnum as the next CEM expansion site, with two production blocks expected to house semiconductor products and a new chemical entity for a leading global agrochemical major. Management expects commercial production from these facilities in Q4 FY27, while pilot-plant commercialisation of semiconductor products for customers in Japan began in October 2026.
Aether is also building a new research and development centre at Site 1+, adjacent to its existing site, with commissioning expected by Q2 FY28. The centre has approximately Rs 100 crore of planned capital expenditure and is designed to house 120 fume hoods and eight technical laboratories for additional CRAMS project capacity.
For FY27, Aether expects total capital expenditure of Rs 300 crore to Rs 350 crore, including about Rs 60 crore at Site Catalyst and the remainder at Magnum. The presentation also cited approximately Rs 83.3 crore of capital expenditure at Magnum in Q1 FY27, alongside work on the semiconductor and agrochemical production blocks.
Material Science accounted for approximately 17.93% of quarterly sales and grew 16.05% year on year. Management expects the sector to become Aether's second-largest revenue contributor through the Milliken allocation at Ascend, Converge polyols sales, output for the European customer and commercial-scale semiconductor-material supplies from Magnum at the start of Q4 FY27.
How has the revenue mix affected Aether's margins and working capital?
Aether reported an earnings before interest, tax, depreciation and amortisation (EBITDA) margin of 31.64% in the first half of financial year 2027 (1H FY27), compared with 30.76% in 1H FY26, an improvement of 88 basis points. Management attributed the increase to the larger CRAMS and CEM mix and LSM pricing despite a nearly threefold increase in logistics costs and elevated raw-material prices.
The shift toward CRAMS and CEM, which contributed more than 60% of revenue, coincided with debtor days declining to 107 at September 30, 2026, from 109 in March 2026. Inventory days increased to 172 from 151 because Aether stocked key raw materials for CEM contracts running ahead of production schedules and for Magnum's two production blocks.
Creditor days remained at 114, while net working capital increased to 165 days at September 30, 2026, from 162 days at March 31, 2026. Management expects the inventory ratio and net working capital to decline over the following six months as Magnum and Strata increase production and sales. Outstanding borrowings at September 30, 2026 comprised Rs 415.2 crore of working-capital loans and Rs 208.5 crore of term loans.
Conclusion
Aether's reported business mix shows capacity moving from LSM toward contract research and contract manufacturing, with CRAMS and CEM supplying 65.97% of quarterly revenue while LSM sales declined 8.35% quarter on quarter. The mix shift coincided with an 88-basis-point increase in 1H FY27 EBITDA margin, although inventory days rose by 21 days as the company prepared for contract deliveries and new production blocks.
The next disclosed milestones are additional Baker Hughes products from Q3 FY27, commercial production at Magnum's semiconductor and agrochemical blocks in Q4 FY27, and commissioning of the new research and development centre by Q2 FY28. Management also expects working-capital days to decline within six months as Strata and Magnum production and sales ramp up.


